Butterfly (IVD -TAQPATH V1 510K) - Clinical Performance Study Protocol - PRJ0003622
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 1,076
- Locations
- 9
- Primary Endpoint
- Clinical performance evaluation of the COVID-19 test
Study Overview
Brief Summary
This prospective clinical performance study is a non-interventional, multi-center study to evaluate the assay performance of the COVID-19 test using upper respiratory specimens. Prospectively collected nasopharyngeal and anterior nasal swabs will be collected from each participant recruited in the study.
Detailed Description
The Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit (referred to as "COVID-19 test") aims to develop a reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2.
The purpose of this study is to evaluate the clinical performance of the TaqPath™ COVID-19 Diagnostic PCR Kit (COVID-19 test) in nasopharyngeal swabs and anterior nasal swabs from symptomatic individuals suspected of COVID-19 by their health care provider.
A composite comparator approach will be used to evaluate the performance of the COVID-19 test which includes the use of three highly sensitive SARS-CoV-2 molecular assays as comparators. Clinical calls will be compared between COVID-19 test and the three composite comparators. The third comparator assay will only be used to test samples that show discrepant clinical calls between the first two comparator methods, for a two-out-of-three result interpretation. The Clinical Performance Study Protocol (CPS Protocol) outlines the clinical sample collection and testing protocols which will be used to satisfy the FDA 510(k) study requirements in the US.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Participants of all ages must meet the following inclusion criteria to be eligible for participation in the study:
- •Ability to provide informed consent or assent (as age-appropriate). Stated willingness and ability to comply with the study procedures including nasopharyngeal and anterior nasal swab collection.
- •Individuals with at least one of the following COVID-19 symptoms:
- •fever or chills
- •congestion or runny nose
- •headache or fatigue
- •muscle or body aches
- •b. new loss of taste or smell c. a new or worsening cough or sore throat d. shortness of breath or difficulty breathing e. decrease in appetite, nausea, vomiting, diarrhea.
- •Subjects suspected of having COVID-19 symptoms for seven (7) or fewer days.
Exclusion Criteria
- •Participants meeting the following criterion will be excluded from the study:
- •Subjects suspected of having COVID-19 symptoms for greater than seven (7) days.
- •Subjects who have provided upper respiratory tract samples for other clinical studies within twenty-four (24) hours
Outcomes
Primary Outcomes
Clinical performance evaluation of the COVID-19 test
Time Frame: Between April 2023 and August 2023
Clinical performance evaluation of the COVID-19 test using a composite comparator approach with upper respiratory specimens to meet PPA and NPA requirements.
Identification of adverse events
Time Frame: Between April 2023 and August 2023
Identify any adverse events or complications associated with the COVID-19 test
Secondary Outcomes
No secondary outcomes reported